BioPlus Acquisition Corp. was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It is focused on identifying opportunities in the healthcare industry across the U.S., EU, Israel and Australasia.
Company profile
Ticker
BIOSU, BIOSW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • QT Imaging • Outset Medical • Fonar ...
SEC CIK
Corporate docs
IRS number
981583272
BIOSU stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
16 Oct 23
25-NSE
Exchange delisting
6 Oct 23
RW
Registration withdrawal request
4 Oct 23
8-K
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate
4 Oct 23
425
Business combination disclosure
15 Sep 23
425
Business combination disclosure
16 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
425
Business combination disclosure
17 Jul 23
Latest ownership filings
SC 13G/A
CANTOR FITZGERALD SECURITIES
12 Feb 24
SC 13G/A
Polar Asset Management Partners Inc.
9 Feb 24
SC 13G/A
Saba Capital Management, L.P.
7 Feb 24
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
19 Jan 24
SC 13D/A
BioPlus Sponsor LLC
12 Jun 23
4
ALEX SERGE VIEUX
12 Jun 23
SC 13G/A
CANTOR FITZGERALD SECURITIES
14 Feb 23
SC 13G/A
Saba Capital Management, L.P.
14 Feb 23
SC 13G
Polar Asset Management Partners Inc.
9 Feb 23
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
2 Feb 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.45 k | 2.45 k | 2.45 k | 2.45 k | 2.45 k | |
Cash burn (monthly) | 10.97 k | 24.35 k | 426.33 k | 180.24 k | 26.30 k | |
Cash used (since last report) | 107.77 k | 239.20 k | 4.19 mm | 1.77 mm | 258.33 k | |
Cash remaining | -105.32 k | -236.75 k | -4.19 mm | -1.77 mm | -255.88 k | |
Runway (months of cash) | -9.6 | -9.7 | -9.8 | -9.8 | -9.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 565.57 mm |
Total shares | 17.63 mm |
Total puts | 0.00 |
Total calls | 214.21 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BioPlus Sponsor | 6.63 mm | $70.15 mm |
Fitzgerald Securities Cantor | 1.60 mm | $0.00 |
Periscope Capital | 867.07 k | $48.56 mm |
Saba Capital Management | 756.25 k | $52.71 mm |
Polar Asset Management Partners | 601.93 k | $33.71 mm |
Shaolin Capital Management | 525.00 k | $29.00 k |
Cowen And | 522.10 k | $29.24 mm |
Linden Advisors | 500.00 k | $34.85 mm |
Calamos Advisors | 500.00 k | $28.00 mm |
GS Goldman Sachs | 412.55 k | $23.10 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jun 23 | BioPlus Sponsor | Class A Ordinary Shares | Conversion | Acquire C | Yes | No | 0 | 5,749,999 | 0.00 | 6,629,999 |
5 Jun 23 | BioPlus Sponsor | Class B Ordinary Shares Class A Ordinary Shares | Conversion | Dispose C | Yes | No | 0 | 5,749,999 | 0.00 | 1 |